Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Tianjin og Shanghai tilslutter sig Cities Changing Diabetes på Verdensdiabetesdagen


News provided by

Novo Nordisk

Nov 14, 2014, 02:00 ET

Share this article

Share toX

Share this article

Share toX

BAGSVÆRD, Danmark, November 14, 2014 /PRNewswire/ --

I dag, på Verdensdiabetesdagen, tilslutter de to kinesiske storbyer Tianjin og Shanghai sig initiativet Cities Changing Diabetes, der er et ambitiøst globalt partnerskabsprogram, som har til formål at bremse udviklingen i forekomsten af diabetes i verdens storbyer. Programmet er iværksat af Novo Nordisk og blev lanceret i Mexico City i marts 2014. Siden har København og senest Houston i USA tilsluttet sig initiativet.

For at se vores Multimedia News Release, venligst besøg:

http://www.multivu.com/players/English/7377451-novo-nordisk-shanghai-diabetes/

     (Logo: http://photos.prnewswire.com/prnh/20120911/559804 )

Ifølge nye tal fra den internationale diabetesforening, IDF, anslås det, at 387 mio. mennesker i verden har diabetes, og at flere end to tredjedele af dem bor i byområder[1]. På globalt plan er der 2-5 gange større risiko for at få type 2-diabetes, hvis man bor i en storby[2]. Cities Changing Diabetes er det første initiativ af sin art, hvis formål det er at få offentlige og private organisationer til at arbejde sammen om at finde bæredygtige løsninger på den store udfordring, verdens storbyer står overfor i forhold til udbredelsen af type 2-diabetes.

Formålet med Cities Changing Diabetes er i første omgang at kortlægge problemet, derefter udveksle ideer og bud på løsninger og til slut udarbejde konkrete handlingsplaner for de storbyer, der deltager i programmet.

Diabetes i Tianjin og Shanghai 

Kina har 96 mio. mennesker med diabetes og dermed en af de højeste forekomster af diabetes i verden[3]. Over halvdelen af dem, der har diabetes i Kina, bor i storbyområder, og Shanghai og Tianjin er nogle af de største storbyer i Kina. Tianjins indbyggertal er fordoblet siden 1995 til omkring 11 mio. mennesker[4], og det anslås, at 9,5% i dag har diabetes[5]. I Shanghai, som har 23,8 mio. indbyggere[6], anslås det, at 12,6% har diabetes[7].

Både The People's Municipal Government of Shanghai og Shanghai Municipal Commission of Health and Family Planning er optaget af at tackle den store udfordring, byen står overfor i forhold til den stigende udbredelse af diabetes. Derfor har myndighederne iværksat en række tiltag for at sætte øget fokus på forebyggelse og behandling af type 2-diabetes og andre kroniske sygdomme. Shanghai hilser derfor alle relevante tiltag, der er baseret på akademisk forskning og innovative partnerskaber, velkomne.

I Tianjin gør myndighederne en målrettet indsats for at fremme en sund livsstil, hvilket er helt afgørende i forhold til at bremse udviklingen i forekomsten af type 2-diabetes. Cities Changing Diabetes passer fint ind de initiativer, National Health and Planning Commission allerede har sat i værk for at bremse udviklingen af type 2-diabetes.

Tianjin Medical Association og Shanghai Diabetes Institute vil stå i spidsen for den indledende analyse for Cities Changing Diabetes i Kina. Det sker i samarbejde med University College London (UCL) i Storbritannien, der er den globale akademiske partner i programmet.

"Cities Changing Diabetes-partnerskabet vil give et solidt grundlag for at identificere fremtidige initiativer, der kan bidrage til at dæmme op for væksten af diabetes i Shanghai," siger professor Jia Weiping fra Shanghai Diabetes Institute.

"Jeg er sikker på, at deltagelsen i Cities Changing Diabetes vil være til gavn for byens forsatte arbejde på at bekæmpe udbredelsen af type 2-diabetes," siger Mr. Xiong Zhi, generalsekretær for Tianjin Medical Association.

Lars Rebien Sørensen, administrerende direktør for Novo Nordisk, hilser de to storbyer velkommen i partnerskabet: "Det er mit håb, at vi gennem samarbejdet i Cities Changing Diabetes kan være med til at hjælpe de to byer i deres bestræbelser på at dæmme op for den kæmpemæssige udfordring, som udbredelsen af type 2-diabetes er, og således aktivt være med til at bidrage med løsninger til, hvordan dette alvorlige sundhedsproblem bedst tackles."

Om Cities Changing Diabetes 

Cities Changing Diabetes er et ambitiøst partnerskabsprogram, der skal dæmme op for det voksende problem, som den hastige udbredelse af diabetes udgør i verdens storbyer. Ifølge nye tal, som International Diabetes Federation (IDF) har offentliggjort i dag, anslås det, at 592 mio. mennesker vil have diabetes i 2035. I dag bor næsten to tredjedele af alle med diabetes i storbyerne, og de, der flytter til byen, har betydeligt større risiko for at udvikle type 2-diabetes end dem, der bliver på landet.

Formålet med Cities Changing Diabetes er i første omgang at kortlægge problemet i udvalgte storbyområder, derefter udveksle ideer og bud på løsninger og udarbejde handlingsplaner for storbyer i hele verden. Det britiske University College London (UCL) er den globale akademisk partner for initiativet, som også omfatter Steno Diabetes Center i Danmark, en af verdens førende institutioner indenfor diabetesbehandling og -forebyggelse, foruden Novo Nordisk.

Se mere på Cities Changing Diabetes - og følg med på Facebook og Twitter.

Om Verdensdiabetesdagen  

Hvert år den 14. november går Novo Nordisk sammen med International Diabetes Federation (IDF) om at støtte op om FN's resolution om diabetes. Dagen markeres overalt i verden af medarbejdere, partnere, mennesker med diabetes og offentligheden for at sætte fokus på diabetessagen.

Dagen er valgt, fordi det er Frederick Bantings fødselsdag. Det var ham, der sammen med Charles Best startede det arbejde, som førte til opdagelsen af insulin i 1921. Siden vedtagelsen af FN's resolution om diabetes i december 2006 er dagen blevet fejret som officiel FN-mærkedag, United Nations World Health Day. Læs mere om kampagnen, som er drevet af International Diabetes Federation. Læs mere om Verdensdiabetesdagen 2014 og slut op om kampen mod diabetes i storbyerne på http://bit.ly/urbanwdd eller følg @NovoNordisk og brug #UrbanDiabetes og/eller #WDD2014 online.

Fotos og dækbilleder til denne pressemeddelelse kan downloades på novonordisk.com.

Referencer 

1. International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2014

2. Mbanya JC et al. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733):2254-2266

3. International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2014

4. United Nations Department of Economic and Social Affairs, World Urbanization Prospects, the 2014 Revision

5. Xu W et al. Detection of Prediabetes and Undiagnosed Type 2 Diabetes: A Large Population-Based Study, Can J of Diabetes 2012 (36):108-113

6. United Nations Department of Economic and Social Affairs, World Urbanization Prospects, the 2014 Revision

7. Li, R. Increasing Prevalence of Type 2 Diabetes in Chinese Adults in Shanghai, Diabetes Care 35:1028-1030, 2012

Yderligere information
Medier:
Katrine Sperling
+45-3079-6718
[email protected]

Video: 
     http://www.multivu.com/players/English/7377451-novo-nordisk-shanghai-diabetes/

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes

Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli®...

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes

Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli®...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Not For Profit

Not For Profit

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.